PeptideComparePancragen — EU research guide.
Pancragen is a synthetic tetrapeptide (Lys-Glu-Asp-Trp) from the Khavinson bioregulator series proposed to support beta-cell differentiation and pancreatic tissue gene regulation. It is studied in the same general research context as Suprefort, another pancreas-targeted bioregulator in the same family.
What is Pancragen?
Pancragen is a synthetic tetrapeptide (Lys-Glu-Asp-Trp) from the Khavinson bioregulator series proposed to support beta-cell differentiation and pancreatic tissue gene regulation. It is studied in the same general research context as Suprefort, another pancreas-targeted bioregulator in the same family.
What does the research show?
Available research centers on glucose and insulin-related markers in animal models and cell cultures, plus one small non-randomised human comparison (33 patients with type 2 diabetes, 30 controls) from the originating group and collaborators. No independently replicated human trial data is publicly available as of mid-2026, and the proposed mechanism remains far less characterized than established metabolic peptides like GLP-1 analogues.
EU legal status
Not approved as a medicine anywhere in the EU. Sold by a small number of specialist research vendors for laboratory metabolic research only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ A structural estimate, derived from each compound's sequence length, cyclisation and oxidation-, deamidation- and light-sensitive residues. Indicative only — not lab-measured per batch.
Pancragen is not yet in our price comparison
We expand EU supplier coverage every month.
References
- Small comparative human study (30 controls, 33 type 2 diabetes patients) co-authored by Khavinson. It reports improved glucose and insulin markers with Pancragen, but is not described as randomised or blinded and I could not verify group sizes per arm or duration. Treat it as hypothesis-generating. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA, Bondarenko EV. Prospects of using Pancragen for correction of metabolic disorders in elderly people. Bull Exp Biol Med. 2011;151(4):454-456. DOI
- Rat study in streptozotocin diabetes: glucose lowering and normalised endothelial adhesion were reported. Animal data from the originating group only; it does not show that the effect carries over to people. Khavinson VKh, Gavrisheva NA, Malinin VV, Chefu SG, Trofimov EL. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. Bull Exp Biol Med. 2007;144(4):559-562. DOIPubMed 18642713
- Cell-culture study: Pancragen raised expression of pancreatic differentiation transcription factors in young and aged cultures. It is a mechanism hint at best, from the originating group. Khavinson VK, Durnova AO, Polyakova VO, et al. Effects of Pancragen on the differentiation of pancreatic cells during their ageing. Bull Exp Biol Med. 2013;154:501-504. DOI
- Study of the endogenous tetrapeptide Lys-Glu-Asp-Trp-NH2, including a chemically induced diabetes model and programmed-cell-death markers. Only the abstract summary was checked; model species and results in detail were not verified. Khavinson VKh, Gapparov MM, Sharanova NE, Vasilyev AV, Ryzhak GA. Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide. Bull Exp Biol Med. 2010;149(3):351-353. DOIPubMed 21246099